<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0703210587
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Xaliptine
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OXALIPLATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        449.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Fareva Unterach GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Fareva Unterach GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HEXAL AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Xaliptine&reg; is an anticancer medicine and contains the active substance oxaliplatin.&nbsp;</p><p>&nbsp;</p><p>Xaliptine&reg; is used for treating bowel cancer after it has been removed by surgery or when it has already spread.&nbsp;</p><p>&nbsp;</p><p>Xaliptine&reg; is used in combination with other anticancer medicines called 5- fluorouracil (5-FU) and&nbsp;folinic&nbsp;acid (FA).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given&nbsp;Xaliptine&reg;:&nbsp;</strong></p><ol><li><p>if you are&nbsp;<strong>allergic&nbsp;</strong>to&nbsp;oxaliplatin&nbsp;</p></li><li><p>if you are<strong>&nbsp;breast-feeding&nbsp;</strong></p></li><li><p>if you already have a&nbsp;<strong>reduced number of blood&nbsp;cells&nbsp;</strong></p></li><li><p>if you already have&nbsp;<strong>tingling and numbness in the fingers and/or toes</strong>, and have&nbsp;<strong>difficulty performing delicate tasks</strong>, such as buttoning&nbsp;clothes&nbsp;</p></li><li><p>if you have<strong>&nbsp;severe kidney&nbsp;problems&nbsp;</strong></p></li></ol><p>&nbsp;</p><p><strong>Warnings and precautions:</strong>&nbsp;</p><p>Talk to your doctor before you are&nbsp;given&nbsp;Xaliptine&reg;&nbsp;</p><p>&nbsp;</p><ul><li><p>if you have ever suffered an allergic reaction to platinum-containing medicines such as carboplatin, cisplatin. Allergic reactions can occur during any oxaliplatin&nbsp;infusion.&nbsp;</p></li><li><p>if you have mild or moderate kidney&nbsp;problems&nbsp;</p></li><li><p>if you have any liver problems or abnormal liver function test results during your&nbsp;treatment&nbsp;</p></li><li><p>If you have or had heart disorders such as an abnormal electrical signal called prolongation of the QT interval, an irregular&nbsp;heart beat, or a family history of heart&nbsp;problems.&nbsp;</p></li></ul><p>&nbsp;</p><p><strong>Other medicines&nbsp;and&nbsp;Xaliptine&reg;&nbsp;</strong></p><p>Tell your doctor if you are using, have recently used or might use any other medicines.&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility&nbsp;</strong></p><p>Pregnancy&nbsp;</p><ul><li><p>It is not recommended that you become pregnant during treatment with oxaliplatin and must use an effective method of contraception. Female patients should take appropriate contraceptive measures during and after cessation of therapy continuing for 4&nbsp;months.&nbsp;</p></li><li><p>If you are pregnant or planning a pregnancy it is very important that you discuss this with your doctor&nbsp;<strong>before</strong>&nbsp;you receive any&nbsp;treatment.&nbsp;</p></li><li><p>If you get pregnant during your treatment, you must immediately inform your&nbsp;doctor.&nbsp;</p></li></ul><p>&nbsp;</p><p><u>Breast-feeding&nbsp;</u></p><ul><li><p>You must not breast-feed while you are treated with&nbsp;oxaliplatin.&nbsp;</p></li></ul><p>&nbsp;</p><p><u>Fertility&nbsp;</u></p><ul><li><p>Oxaliplatin may have an anti-fertility effect, which could be irreversible. Male patients should seek advice on conservation of sperm prior to&nbsp;treatment.&nbsp;</p></li></ul><ul><li><p>Male patients are advised not to father a child during treatment and until 6 months after treatment, and to take appropriate contraceptive measures during this&nbsp;time.&nbsp;</p></li></ul><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.&nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines&nbsp;</strong></p><p>Oxaliplatin treatment may result in an&nbsp;increase&nbsp;risk of dizziness, nausea and vomiting, and other neurological symptoms that affect walking and balance. If this happens you should not drive or operate machinery. If you have vision problems while taking Oxaliplatin, do not drive, operate heavy machines, or engage in dangerous activities.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine will be administered by medical personnel; do not take it yourself.&nbsp;Xaliptine&reg; is intended in adults only.&nbsp;</p><p>&nbsp;</p><p><strong>Dosage&nbsp;</strong></p><p>The dose of&nbsp;Xaliptine&reg;&nbsp;is based on your body surface area. This is calculated from your height and weight.&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>The usual dose for adults including the elderly is 85 mg/m2&nbsp;of body surface area. The dose you receive will also depend on results of blood tests and whether you have previously experienced side effects with&nbsp;Xaliptine&reg;.&nbsp;</p><p>&nbsp;</p><p><strong>Method and route of administration&nbsp;</strong></p><ul><li><p>Xaliptine&reg;&nbsp;will be prescribed for you by a specialist in cancer&nbsp;treatment.&nbsp;</p></li></ul><ul><li><p>You will be treated by a healthcare professional, who will have made up the required dose of&nbsp;Xaliptine&reg;.&nbsp;</p></li><li><p>Xaliptine&reg;&nbsp;is given by slow injection into one of your veins (an intravenous infusion) over a&nbsp;2 to 6 hour&nbsp;period. If feelings of discomfort or pain arise at the injection site inform the healthcare professionals&nbsp;immediately.&nbsp;</p></li><li><p>Xaliptine&reg;&nbsp;will be given to you at the same time as&nbsp;folinic&nbsp;acid and before the infusion of 5&nbsp;fluorouracil.&nbsp;</p></li></ul><p>&nbsp;</p><p><strong>Frequency of administration&nbsp;</strong></p><p>You should usually receive your infusion once every 2 weeks.&nbsp;</p><p>&nbsp;</p><p><strong>Duration of treatment&nbsp;</strong></p><p>The duration of the treatment will be determined by your doctor.&nbsp;</p><p>Your treatment will last a maximum of 6 months when used after complete resection of your&nbsp;tumour.&nbsp;</p><p>&nbsp;</p><p><strong>If you received more&nbsp;Xaliptine&reg;&nbsp;than you should&nbsp;</strong></p><p>As this medicine is administered by a healthcare professional it is highly unlikely that you will be given too much or too little.&nbsp;</p><p>In case of&nbsp;overdose&nbsp;you may experience increased side effects. Your doctor may give you appropriate treatment for these side effects.&nbsp;</p><p>&nbsp;</p><p><strong>If administration of&nbsp;Xaliptine&reg;&nbsp;is forgotten&nbsp;</strong></p><p>Your doctor will decide&nbsp;on&nbsp;what time you will receive this medicine. If you think you missed a dose, please contact your doctor as soon as possible.&nbsp;</p><p>&nbsp;</p><p>If you have any questions about your&nbsp;treatment&nbsp;ask your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.&nbsp;</p><p>&nbsp;</p><p><strong>If you experience any side&nbsp;effect&nbsp;it is important that you inform your doctor before your next treatment.&nbsp;</strong></p><p>&nbsp;</p><p><strong>Tell your doctor&nbsp;immediately,&nbsp;if you notice any of the following:&nbsp;</strong></p><ul><li><p>Symptoms&nbsp;of&nbsp;an&nbsp;allergic&nbsp;or&nbsp;anaphylactic&nbsp;reaction&nbsp;with&nbsp;sudden&nbsp;signs&nbsp;such&nbsp;as&nbsp;rash,&nbsp;itching&nbsp;or&nbsp;hives&nbsp;on&nbsp;the&nbsp;skin,&nbsp;difficulties&nbsp;in&nbsp;swallowing,&nbsp;swelling&nbsp;of&nbsp;the&nbsp;face,&nbsp;lips,&nbsp;tongue&nbsp;or&nbsp;other&nbsp;parts&nbsp;of&nbsp;the&nbsp;body,&nbsp;shortness&nbsp;of&nbsp;breath,&nbsp;wheezing&nbsp;or&nbsp;trouble&nbsp;breathing,&nbsp;extreme&nbsp;tiredness&nbsp;(you&nbsp;may&nbsp;feel&nbsp;you&nbsp;are&nbsp;going&nbsp;to&nbsp;faint). In&nbsp;the&nbsp;majority&nbsp;of&nbsp;cases,&nbsp;these&nbsp;symptoms&nbsp;occurred&nbsp;during&nbsp;the&nbsp;infusion&nbsp;or&nbsp;immediately&nbsp;after&nbsp;but&nbsp;delayed&nbsp;allergic&nbsp;reactions&nbsp;have&nbsp;also&nbsp;been&nbsp;observed&nbsp;hours&nbsp;or&nbsp;even&nbsp;days&nbsp;after&nbsp;the&nbsp;infusion&nbsp;(very&nbsp;common)&nbsp;</p></li><li><p>Abnormal bruising, bleeding, or signs of infection such as a sore throat and high temperature (very&nbsp;common)&nbsp;</p></li><li><p>Persistent or severe&nbsp;diarrhoea&nbsp;or vomiting (very&nbsp;common)&nbsp;</p></li><li><p>Respiratory symptoms such as dry or wet cough, difficulties in breathing or crackles (very common), shortness of breath and wheezing as these may be indicators of a serious lung disease that may lead to&nbsp;death&nbsp;</p></li></ul><ul><li><p>Stomatitis/mucositis (sore lips or mouth ulcers) (very&nbsp;common)&nbsp;</p></li><li><p>Presence of blood or dark brown coffee-coloured&nbsp;particles in your vomit&nbsp;(common)&nbsp;</p></li><li><p>A group of symptoms such as headache, altered mental functioning, seizures and abnormal vision from blurriness to vision loss (symptoms of reversible posterior leukoencephalopathy syndrome, a rare neurological disorder)&nbsp;(rare)&nbsp;</p></li><li><p>Stroke symptoms (including sudden severe headache, confusion, trouble seeing in one or both eyes, numbness or weakness of face, arm or leg usually on one side, face drooping, trouble walking, dizziness, loss of balance and speech&nbsp;difficulty)&nbsp;</p></li><li><p>Extreme&nbsp;tiredness&nbsp;with&nbsp;decreased&nbsp;number&nbsp;of&nbsp;red&nbsp;blood&nbsp;cells,&nbsp;and&nbsp;shortness&nbsp;of&nbsp;breath&nbsp;(haemolytic&nbsp;anaemia)&nbsp;(rare), alone&nbsp;or&nbsp;combined&nbsp;with&nbsp;low&nbsp;platelet&nbsp;count,&nbsp;abnormal&nbsp;bruising&nbsp;(thrombocytopenia)&nbsp;(rare)&nbsp;and&nbsp;kidney&nbsp;disease&nbsp;where&nbsp;you&nbsp;pass&nbsp;little&nbsp;or&nbsp;no&nbsp;urine&nbsp;(symptoms&nbsp;of&nbsp;Haemolytic-uraemic&nbsp;syndrome) (frequency&nbsp;not&nbsp;known)&nbsp;</p></li></ul><p>&nbsp;</p><p><strong>Other known side effects of&nbsp;Xaliptine&reg;&nbsp;are:&nbsp;</strong></p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10 people):&nbsp;</p><ul><li><p>Xaliptine&reg;&nbsp;can affect the nerves (peripheral neuropathy). You may feel a tingling and/or numbness in the fingers, toes, around the mouth or in the throat, which may sometimes occur in association with&nbsp;cramps.&nbsp;</p></li></ul><p>These effects are often triggered by exposure to&nbsp;cold&nbsp;e.g.&nbsp;opening a refrigerator or holding a cold drink. You may also have difficulty in performing delicate tasks, such as buttoning clothes. Although in&nbsp;the majority of&nbsp;cases these symptoms resolve themselves completely&nbsp;there is a possibility of persistent symptoms of peripheral sensory neuropathy after the end of the treatment.&nbsp;</p><p>Some people have experienced a tingling, shock-like sensation passing down&nbsp;the&nbsp;arms or trunk when&nbsp;the&nbsp;neck is flexed.&nbsp;</p><ul><li><p>Xaliptine&reg;&nbsp;can&nbsp;sometimes&nbsp;cause&nbsp;an&nbsp;unpleasant&nbsp;sensation&nbsp;in&nbsp;the&nbsp;throat,&nbsp;in&nbsp;particular&nbsp;when&nbsp;swallowing,&nbsp;and&nbsp;give&nbsp;the&nbsp;sensation&nbsp;of&nbsp;shortness&nbsp;of&nbsp;breath.&nbsp;This&nbsp;sensation,&nbsp;if&nbsp;it&nbsp;happens,&nbsp;usually&nbsp;occurs&nbsp;during&nbsp;or&nbsp;within&nbsp;hours&nbsp;of&nbsp;the&nbsp;infusion&nbsp;and&nbsp;may&nbsp;be&nbsp;triggered&nbsp;by&nbsp;exposure&nbsp;to&nbsp;the&nbsp;cold.&nbsp;</p></li></ul><p>Although unpleasant, it will not last long and goes away without the need for any treatment. Your doctor may decide to alter your treatment as a result.&nbsp;</p><p>&nbsp;</p><ul><li><p>Xaliptine&reg;&nbsp;may cause diarrhea, mild nausea (feeling sick) and vomiting (being sick);&nbsp;however&nbsp;medication to prevent the sickness is usually given to you by your doctor before treatment and may be continued after&nbsp;treatment.&nbsp;</p></li><li><p>Xaliptine&reg;&nbsp;causes&nbsp;temporary&nbsp;reduction&nbsp;in&nbsp;the&nbsp;number&nbsp;of&nbsp;blood&nbsp;cells.&nbsp;The&nbsp;reduction&nbsp;of&nbsp;red&nbsp;cells&nbsp;may&nbsp;cause&nbsp;anaemia&nbsp;(a&nbsp;reduction&nbsp;of&nbsp;red&nbsp;cells),&nbsp;abnormal&nbsp;bleeding&nbsp;or&nbsp;bruising&nbsp;(due&nbsp;to&nbsp;a&nbsp;reduction&nbsp;in&nbsp;platelets).&nbsp;The&nbsp;reduction&nbsp;in&nbsp;white&nbsp;blood&nbsp;cells&nbsp;may&nbsp;make&nbsp;you&nbsp;prone&nbsp;to&nbsp;infections.&nbsp;</p></li></ul><p>Your doctor will take blood to check that you have sufficient blood cells before you start treatment and before each subsequent course.&nbsp;</p><ul><li><p>Sensation of discomfort close to or at the injection site during the&nbsp;infusion,&nbsp;</p></li><li><p>Fever, rigors (tremors), mild or severe tiredness, body&nbsp;pain&nbsp;</p></li></ul><ul><li><p>Weight changes, loss or lack of appetite, taste disorders,&nbsp;constipation&nbsp;</p></li><li><p>Headache, back&nbsp;pain&nbsp;</p></li><li><p>Swelling of the nerves to your muscles, neck stiffness, abnormal tongue sensation possibly altering&nbsp;speech&nbsp;</p></li><li><p>Stomach&nbsp;pain&nbsp;</p></li><li><p>Abnormal bleeding including nose&nbsp;bleeds&nbsp;</p></li></ul><ul><li><p>Coughing,&nbsp;difficulty in&nbsp;breathing&nbsp;</p></li><li><p>Allergic reactions, skin rash which may be red and itchy, mild hair loss&nbsp;(alopecia)&nbsp;</p></li><li><p>Alteration in blood tests including those relating to abnormalities in liver&nbsp;function&nbsp;</p></li></ul><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people):&nbsp;</p><ul><li><p>Infection due to a reduction in white blood&nbsp;cells,&nbsp;</p></li><li><p>Serious infection of the blood in addition to a reduction in white blood cells (neutropenic sepsis), which may be&nbsp;fatal,&nbsp;</p></li><li><p>Reduction in white blood cells accompanied by fever &gt; 38.3&deg;C or a prolonged fever &gt; 38&deg;C for more than one hour (febrile&nbsp;neutropenia)&nbsp;</p></li><li><p>Indigestion and heartburn, flushing, hiccups and&nbsp;dizziness&nbsp;</p></li><li><p>Increased sweating and nail disorders, flaking&nbsp;skin&nbsp;</p></li></ul><ul><li><p>Chest pain&nbsp;</p></li><li><p>Lung disorders and runny&nbsp;nose&nbsp;</p></li><li><p>Joint pain and bone&nbsp;pain&nbsp;</p></li><li><p>Pain on passing urine and changes of kidney function, change of frequency of urination,&nbsp;dehydration&nbsp;</p></li><li><p>blood in the urine/ stools, swelling of the veins, clots in the&nbsp;lung&nbsp;</p></li></ul><ul><li><p>High blood&nbsp;pressure&nbsp;</p></li><li><p>Depression and&nbsp;insomnia&nbsp;</p></li><li><p>Conjunctivitis and visual&nbsp;problems&nbsp;</p></li><li><p>Decreased levels of calcium in the&nbsp;blood&nbsp;</p></li><li><p>Fall&nbsp;</p></li></ul><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people):&nbsp;</p><ul><li><p>Serious infection of the blood (sepsis), which may be&nbsp;fatal,&nbsp;</p></li><li><p>Blockage or swelling of the&nbsp;bowel&nbsp;</p></li><li><p>Nervousness&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p></li></ul><p>&nbsp;</p><p><strong>Rare</strong>&nbsp;(may affect up to 1 in 1,000 people):&nbsp;</p><ul><li><p>Loss of&nbsp;hearing&nbsp;</p></li><li><p>Scarring and thickening in the lungs with difficulties in breathing, sometimes fatal (interstitial lung&nbsp;disease),&nbsp;</p></li><li><p>Reversible short-term loss of&nbsp;vision&nbsp;</p></li><li><p>Unexpected bleeding or bruising due to widespread blood clots throughout the small blood vessels of the body (disseminated intravascular coagulation), which may be&nbsp;fatal.&nbsp;</p></li></ul><p><strong>Very rare</strong> (may affect up to 1 in 10,000 people):&nbsp;</p><ul><li><p>Kidney disease where you pass little or no urine (symptoms of acute renal&nbsp;failure)&nbsp;</p></li><li><p>Vascular disorders of&nbsp;liver.&nbsp;</p></li></ul><p>&nbsp;</p><p><strong>Frequency not known </strong>(cannot be estimated from the available data):&nbsp;</p><ul><li><p>Allergic vasculitis (inflammation of blood&nbsp;vessels)&nbsp;</p></li><li><p>Auto-immune reaction leading to reduction of all blood cell lines (autoimmune pancytopenia),&nbsp;pancytopenia&nbsp;</p></li><li><p>Serious infection of the blood and low blood pressure (septic shock), which may be&nbsp;fatal&nbsp;</p></li><li><p>Convulsion (uncontrolled shaking of the&nbsp;body)&nbsp;</p></li></ul><ul><li><p>Spasm of the throat causing difficulty in&nbsp;breathing&nbsp;</p></li><li><p>Extreme&nbsp;tiredness&nbsp;with&nbsp;decreased&nbsp;number&nbsp;of&nbsp;red&nbsp;blood&nbsp;cells,&nbsp;and&nbsp;shortness&nbsp;of&nbsp;breath&nbsp;(haemolytic&nbsp;anaemia),&nbsp;alone&nbsp;or&nbsp;combined&nbsp;with&nbsp;low&nbsp;platelet&nbsp;count&nbsp;and&nbsp;kidney&nbsp;disease&nbsp;where&nbsp;you&nbsp;pass&nbsp;little&nbsp;or&nbsp;no&nbsp;urine&nbsp;(symptoms&nbsp;of&nbsp;Haemolytic-uraemic&nbsp;syndrome), which&nbsp;may&nbsp;be&nbsp;fatal,&nbsp;have&nbsp;been&nbsp;reported&nbsp;</p></li><li><p>Abnormal heart rhythm (QT prolongation), that can be seen on electrocardiogram (ECG), which may be&nbsp;fatal&nbsp;</p></li><li><p>Myocardial infarction (Heart attack),&nbsp;anginapectoris&nbsp;(pain or uncomfortable feeling in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the&nbsp;chest)&nbsp;</p></li><li><p>Muscle pain and swelling, in combination with weakness, fever, or red-brown urine (symptoms of muscle damage called rhabdomyolysis), which may be&nbsp;fatal&nbsp;</p></li></ul><ul><li><p>Oesophageal&nbsp;inflammation (inflammation of the lining of the esophagus - the tube that connects your mouth with your stomach resulting in pain and swallowing&nbsp;difficulty)&nbsp;</p></li><li><p>Abdominal pain, nausea, bloody vomit or vomit that looks like &quot;coffee grounds&rdquo;, or&nbsp;darkcolored/tarry stools (symptoms of gastrointestinal ulcer, with potential bleeding or perforation), which may be&nbsp;fatal&nbsp;</p></li><li><p>Decreased blood flow to the intestine/bowel (intestinal&nbsp;ischaemia), which may be&nbsp;fatal&nbsp;</p></li><li><p>Risk&nbsp;of&nbsp;new&nbsp;cancers.&nbsp;Leukemia,&nbsp;a&nbsp;form&nbsp;of&nbsp;blood&nbsp;cancer,&nbsp;has&nbsp;been&nbsp;reported&nbsp;in&nbsp;patients&nbsp;after&nbsp;taking&nbsp;Xaliptine&reg;&nbsp;in&nbsp;combination&nbsp;with&nbsp;certain&nbsp;other&nbsp;medicines.&nbsp;Talk&nbsp;to&nbsp;your&nbsp;doctor&nbsp;about&nbsp;the&nbsp;potential&nbsp;for&nbsp;increased&nbsp;risk&nbsp;of&nbsp;this&nbsp;type&nbsp;of&nbsp;cancer&nbsp;when&nbsp;taking&nbsp;Xaliptine&reg;&nbsp;and&nbsp;certain&nbsp;other&nbsp;medicines.&nbsp;</p></li></ul><p>&nbsp;</p><p><strong>Reporting of side effects&nbsp;</strong></p><p>If you&nbsp;get&nbsp;any side effects, talk to your doctor. This includes any possible side effects not listed in&nbsp;this leaflet.&nbsp;By reporting side&nbsp;effects you&nbsp;can help provide more information on the safety of this medicine.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of&nbsp;the sight&nbsp;and reach of children.&nbsp;</p><p>&nbsp;</p><p>Xaliptine&reg;&nbsp;should not&nbsp;come into contact with&nbsp;the eyes or skin. If there is any accidental spillage, tell the doctor or nurse immediately.&nbsp;</p><p>&nbsp;</p><p>Prior to mixing this medicinal product must be kept in the outer carton in order to be protected from light and must not be frozen.&nbsp;</p><p>&nbsp;</p><p>Do not store above 30&deg;C.&nbsp;</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the label after EXP. The expiry date refers to the last day of that month.&nbsp;</p><p>&nbsp;</p><p>When the infusion has finished,&nbsp;Xaliptine&reg;&nbsp;will be disposed of carefully by the doctor or nurse.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li><p>The active substance is&nbsp;Oxaliplatin.&nbsp;</p></li><li><p>The other ingredient is Water for&nbsp;injections&nbsp;</p></li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Clear, colourless solution. It is free from visible particles. 


1 ml of solution contains 5 mg oxaliplatin as active ingredient. This medicinal product is a concentrate for solution for infusion. 

10 ml of concentrate for solution for infusion contain 50 mg of oxaliplatin. 20 ml of concentrate for solution for infusion contain 100 mg of oxaliplatin. 30 ml of concentrate for solution for infusion contain 150 mg of oxaliplatin. 40 ml of concentrate for solution for infusion contain 200 mg of oxaliplatin. 50 ml of concentrate for solution for infusion contain 250 mg of oxaliplatin 



Pack sizes: 

50mg/10ml: 1 vial, 5 vials, 10 vials 

100mg/20ml: 1 vial 

150mg/30ml: 1 vial 

200mg/40ml: 1 vial 

250mg/50ml: 1 vial 



With or without a protective plastic overwrap (OncoSafe®). 


Not all pack sizes may be marketed. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing&nbsp;Authorisation&nbsp;Holder&nbsp;</strong></p><p>Hexal AG,&nbsp;Holzkirchen,&nbsp;&nbsp;</p><p>&nbsp;Germany&nbsp;</p><p>&nbsp;</p><p><strong>Manufacturer&nbsp;</strong></p><p>&nbsp;Fareva&nbsp;Unterach&nbsp;GmbH,&nbsp;</p><p>UNTERACH,&nbsp;&nbsp;</p><p>Austria&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>عقار زاليبتين&reg; هو دواء مُضاد للسرطان ويحتوي على المادة الفعَّالة أوكساليبلاتين.</p><p>&nbsp;</p><p>يُستَخدَم عقار زاليبتين&reg; لعلاج سرطان الأمعاء بعد إزالته عن طريق إجراء جراحة أو عند انتشاره بالفعل.</p><p>&nbsp;</p><p>&nbsp;</p><p>يُستَخدَم عقار زاليبتين&reg; بمصاحبة أدوية أخرى مُضادة للسرطان تُسمى 5-فلورويوراسيل وحَمْض الفولينيك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب عدم إعطائك عقار زاليبتين&reg; في الحالات التَّالية:</strong></p><p>1. إذا كنت تعاني من حساسية تجاه أوكساليبلاتين</p><p>2. إذا كنتِ مرضعًا</p><p>3. إذا كان لديك بالفعل نقص في عدد خلايا الدَّم</p><p>4. إذا كنت تُعاني بالفعل من الوخز والتَّنميل في أصابع اليدين و/أو القدمين، وكان لديك صعوبة في القيام بالمهام الدقيقة، مثل تزرير الملابس</p><p>5. إذا كان لديك مشاكل شديدة بالكُلى.</p><p>&nbsp;</p><p><strong>تحذيرات واحتياطات:</strong></p><p>تحدَّث إلى طبيبك قبل أن يتم إعطاؤك عقارزاليبتين&reg;</p><p>&nbsp;</p><p>&middot; إذا كنت قد عانيت من قبل من تفاعل حساسية تجاه الأدوية التي تحتوي على البلاتين مثل كاربوبلاتين وسِيسْبلاتين. من الممكن حدوث تفاعلات حساسية أثناء إعطاء عقار أوكساليبلاتين عن طريق التسريب.</p><p>&middot; إذا كنت تُعاني من مشاكل طفيفة أو متوسطة الشدة في الكُلى.</p><p>&middot; إذا كنت تُعاني من أي مشاكل في الكبد أو كانت نتائج اختبارات وظائف الكبد غير طبيعية أثناء علاجك.</p><p>&middot; إذا كان لديك أو قد كان لديك اضطرابات بالقلب مثل: إشارة كهربائية غير طبيعية تُسمى &quot;إطالة فترة QT&quot; أو عدم انتظام ضربات القلب أو لديك تاريخ عائلي من الإصابة بمشاكل القلب.</p><p>&nbsp;</p><p><strong>تناوُل أدوية أخرى مع عقار زاليبتين&reg;</strong></p><p>يُرجى إبلاغ طبيبك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى.</p><p>&nbsp;</p><p><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p>&nbsp;</p><p><u>الحمل</u></p><p>&middot; يُوصى بتجنُّب الحَمْل أثناء العلاج بأوكساليبلاتين ويجب استخدام وسائل فعَّالة لمنع الحَمْل. يجب على المريضات اتخاذ التَّدابير المناسبة لمنع الحَمْل أثناء وبعد التَّوقف عن العلاج ولمدة 4 أشهر بعد التَّوقف.</p><p>&middot; إذا كنتِ حاملًا أو تخططين للحَمْل فمن المُهِم للغاية أن تناقشي هذا الأمر مع طبيبكِ قبل أن تتلقي أي علاج.</p><p>&middot; إذا أصبحتِ حاملًا أثناء علاجكِ، فيجب أن تبلغي طبيبكِ فورًا.</p><p>&nbsp;</p><p><u>الرضاعة الطبيعية</u></p><p>&middot; يجب عليكِ تجنُّب ممارسة الرضاعة الطبيعية أثناء تلقيكِ العلاج بأوكساليبلاتين.</p><p>&nbsp;</p><p><u>الخصوبة</u></p><p>&middot; قد يكون لأوكساليبلاتين تأثير مضاد للخصوبة، وهو تأثير قد يكون غير قابل للارتداد. ينبغي على المرضى من الذكور أن يطلبوا الاستشارة فيما يتعلق بحفظ الحيوانات المنوية قبل العلاج.</p><p>&middot; يُنصَح المرضى من الذكور بعدم الإنجاب أثناء العلاج وحتى 6 أشهر بعد الانتهاء من العلاج، كما أن عليهم اتخاذ التَّدابير المناسبة لمنع حدوث حَمْل خلال هذه المدة.</p><p>&nbsp;</p><p>استشر طبيبك أو الصيدلي قبل تناول أي دواء.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p>قد يُؤدي العلاج بأوكساليبلاتين إلى زيادة مخاطر التعرُّض لدوخة وغثيان وقيء وغير ذلك من الأعراض العصبية التي تُؤثر على المشي والتَّوازن. إذا حدث ذلك فيجب تجنُّب قيادة المركبات أو تشغيل الآلات. إذا كنت تُعاني من مشاكل في الرؤية أثناء تناوُل أوكساليبلاتين، فلا تقد المركبات أو تشغل الآلات الثقيلة أو تشارك في أنشطة خطرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُستَخدَم هذا الدَّواء من قِبَل الطاقم الطبي؛ فلا تتناوله بنفسك. عقار زاليبتين&reg; مخصص للبالغين فقط.</p><p>&nbsp;</p><p><strong>الجرعة</strong></p><p>تعتمد جرعة عقار زاليبتين&reg;على مساحة سطح الجسم لديك. ويتم حساب ذلك من خلال قياس طولك ووزنك.</p><p>&nbsp;</p><p>الجرعة المُوصى بها للبالغين بما في ذلك كبار السن هي 85 مجم/ متر مربع من مساحة سطح الجسم. ستعتمد أيضًا الجرعة التي تتلقاها على نتائج اختبارات الدَّم وما إذا كنت قد تعرَّضت من قبل لآثار جانبية مُصاحِبة لعقار زاليبتين&reg; أم لا.</p><p>&nbsp;</p><p><strong>أسلوب وطريقة الإعطاء</strong></p><p>&middot; سيُوصَف لك عقار زاليبتين&reg; من قِبَل طبيب متخصص في علاج السرطان.</p><p>&middot; ستتلقى العلاج من قِبَل أخصائي الرّعاية الصحية، وهو بدوره سيحدد الجرعة اللازمة من عقار زاليبتين&reg;</p><p>&middot; يُعطى عقار زاليبتين&reg; عن طريق الحَقْن البطيء في أحد الأوردة (التَّسريب الوريدي) على مدار فترة زمنية قدرها ساعتان إلى 6 ساعات. إذا حدث شعور بالإنزعاج أو الألم في موضع الحَقْن فأبلغ أخصائيي الرّعاية الصحية فورًا.</p><p>&middot; سيُعطى لك عقار زاليبتين&reg; بالتَّزامن مع حَمْض الفولينيك وقبل تسريب 5-فلورويوراسيل.</p><p>&nbsp;</p><p><strong>معدل إعطاء الدَّواء</strong></p><p>يجب أن تتلقى عادةً التَّسريب مرّة واحدة كل أسبوعين.</p><p>&nbsp;</p><p><strong>مدة العلاج</strong></p><p>مدة العلاج سيحددها طبيبك.</p><p>سيستمر علاجك لمدة أقصاها 6 أشهر عند استخدامه بعد الاستئصال الكامل للورم.</p><p>&nbsp;</p><p><strong>إذا تلقيت كمية أكبر مما يجب من عقار زاليبتين&reg;</strong></p><p>نظرًا إلى أنَّ هذا الدَّواء يُعطى من قِبَل أخصائي الرّعاية الصحية، فمن غير المُرجَّح على الإطلاق أن يتم إعطاؤك كمية أكثر أو أقل مما يجب.</p><p>&nbsp;</p><p>في حال تلقي جرعة زائدة، قد تتعرَّض لزيادة الآثار الجانبية. قد يعطيك طبيبك العلاج المناسب لهذه الآثار الجانبية.</p><p>&nbsp;</p><p><strong>في حال إغفال تلقي عقار زاليبتين&reg;</strong></p><p>سيحدد طبيبك الوقت الذين ستتلقى فيه هذا الدَّواء. وإذا كنت تعتقد أنك قد أغفلت إحدى الجرعات، فيُرجى الاتصال بطبيبك بأسرع ما يمكن.</p><p>&nbsp;</p><p>إذا كانت لديك أية أسئلة، حول علاجك، اسأل طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء أعراضًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p>&nbsp;</p><p><strong>إذا تعرَّضت لأية آثار جانبية فمن المُهِم أن تبلغ طبيبك قبل علاجك التَّالي.</strong></p><p>&nbsp;</p><p><strong>يُرجى إبلاغ طبيبك فورًا إذا لاحظت أيًّا مما يلي:</strong></p><p>&nbsp;</p><p>&middot; أعراض تفاعل الحساسية أو التفاعل التَّأَقِيّ مع علامات مفاجئة مثل الطفح الجلدي أو الحكّة أو الشرى على الجلد، صعوبات البلع، تورُّم الوجه أو الشفتين أو اللسان أو أجزاء أخرى من الجسم، ضيق التنفس، أزيز بالصدر أو مشاكل في التنفس، تعب شديد (قد تشعر بأنك ستتعرض لإغماء). في أغلب الحالات تحدث هذه الأعراض أثناء التسريب أو فور الانتهاء منه ولكن لُوحظ أيضًا حدوث تفاعلات حساسية متأخرة بعد ساعات بل وأيام من التَّسريب (شائعة جدًّا)</p><p>&middot; كدمات غير طبيعية، نزيف، أو علامات عدوى مثل التهاب الحَلْق وارتفاع درجة الحرارة (شائعة جدًّا).</p><p>&middot; إسهال أو قيء مستمر أو شديد (شائعة جدًّا).</p><p>&middot; أعراض في الجهاز التَّنفسي مثل: السُّعال الجاف أو الرطب، صعوبات في التَّنفس أو خشخشة (شائعة جدًّا)، ضيق بالتنفس وأزيز بالصدر؛ إذ قد تكون هذه مؤشرات على الإصابة بمرض رئوي خطير قد يُؤدي إلى الوفاة.</p><p>&middot; التهاب الفم/ التهاب الغشاء المخاطي (التهاب الشفتين أو قُرَح الفم) (شائعة جدًّا)</p><p>&middot; وجود دم أو جسيمات ذات لون بني داكن بلون القهوة في القيء (شائعة)</p><p>&middot; مجموعة من الأعراض مثل الصداع، تغير الوظائف العقلية، نوبات تشنُّجية ورؤية غير طبيعية من عدم وضوح الرؤية إلى فقدان البصر (أعراض متلازمة اعْتِلال بَيضاءِ الدِّماغِ الخلفي القابل للارتداد، اضطراب نادر يصيب الجهاز العصبي). (نادرة)</p><p>&middot; أعراض السكتة الدماغية (بما في ذلك الصداع المفاجئ الشديد، الارتباك، مشاكل في الرؤية بإحدى العينين أو كليهما، تنميل أو ضعف بالوجه أو الذراع أو الساق ويكون عادةً على جانب واحد، تهدُّل الوجه، مشاكل في المشي، الدوخة، فقدان التوازن وصعوبة التكلم).</p><p>&middot; تعب شديد مع انخفاض عدد خلايا الدَّم الحمراء وضيق التَّنفس (فقر الدَّم الانحلالي) (نادرة) وحده أو بمصاحبة انخفاض عدد الصفائح الدَّموية، كدمات غير طبيعية (نقص الصَّفائح الدَّموية) ومرض كُلوي من أعراضه قلة التبوُّل أو عدم التبوُّل (أعراض متلازمة انحلال الدَّم اليوريمي) (معدل التكرار غير معروف).</p><p>&nbsp;</p><p><strong>آثار جانبية أخرى معروفة لعقار زاليبتين&reg;:</strong></p><p>&nbsp;</p><p><strong>شائعة جدًّا</strong> (قد تُؤثر على أكثر من شخص واحد من بين كل 10 أشخاص):</p><p>&middot; يُمكِن أن يُؤثر عقارزاليبتين&reg; على الأعصاب (اعتلال العصب الطرفي). قد تشعر بوخز و/أو تنميل في أصابع اليدين أو القدمين أو حول الفم أو في الحَلْق قد يحدث في بعض الأحيان بمصاحبة التقلصات.</p><p>تحدث هذه الآثار في أغلب الأحيان نتيجة التعرُّض للبرودة، على سبيل المثال: فتح الثلاجة أو الإمساك بمشروب بارد. قد تواجه صعوبة أيضًا في القيام بالمهام الدقيقة، مثل تزرير الملابس. على الرغم أنه في غالبية الحالات تزول هذه الأعراض تمامًا إلا أنَّ هناك احتمالية لاستمرار أعراض الاعتلال الحسي للأعصاب الطرفية بعد نهاية العلاج.</p><p>تعرَّض بعض الأشخاص لوخز أو إحساس يشبه الصدمة عند تمرير الذراع لأسفل أو في الجذع عند ثني الرقبة.</p><p>&middot; وقد يُسبب عقار زاليبتين&reg; في بعض الأحيان إحساسًا بالضيق في الحَلْق، لا سيَّما عند البلع، ويعطي إحساسًا بضيق التنفس. إذا حدث هذا الإحساس فإنه يحدث عادةً أثناء أو خلال ساعات التَّسريب وقد يحفزه التعرُّض للبرودة.</p><p>على الرَّغم من كونه مزعجًا، إلا أنه لن يستمر طويلًا ويزول عادةً دون الحاجة إلى أي علاج. قد يقرر طبيبك تغيير علاجك نتيجة لذلك.</p><p>&middot; قد يُسبب عقارزاليبتين&reg; إِسْهالًا وغثيانًا طفيفًا (شعورًا بالإعياء) وقيئًا (الإصابة بالإعياء)؛ مع ذلك، يعطي لك طبيبك عادةً علاجًا للوقاية من الإعياء قبل العلاج وقد تتم مواصلته بعد العلاج</p><p>&middot; يُسبب عقار زاليبتين&reg; انخفاضًا مؤقتًا في عدد خلايا الدَّم. انخفاض عدد خلايا الدَّم قد يُسبب فقر الدَّم (انخفاض خلايا الدَّم)، نزيفًا غير طبيعي أو كدمات (نتيجة انخفاض في الصفائح الدَّموية). قد يجعلك الانخفاض في خلايا الدَّم البيضاء عُرضة للعدوى.</p><p>سيسحب طبيبك عينة دم؛ للتَّأكد من أنَّ لديك خلايا دم كافية قبل أن تبدأ العلاج وقبل كل دورة لاحقة.</p><p>&middot; إحساس بالانزعاج بالقرب من أو في موضع الحَقْن أثناء التَّسريب،</p><p>&middot; حُمّى، ارتعاش (ارتجاف)، تعب طفيف أو شديد، ألم بالجسم.</p><p>&middot; تغيُّرات في الوزن، فقدان أو قلة الشهية، اضطرابات التَّذوق، إمساك.</p><p>&middot; صُداع، ألم بالظهر.</p><p>&middot; تورُّم الأعصاب الموصلة للعضلات، تصلب الرقبة، إحساس غير طبيعي في اللسان ربما يغير من طريقة الكلام.</p><p>&middot; ألم بالمعدة.</p><p>&middot; نزيف غير طبيعي يشمل نزيفًا من الأنف (رعافًا).</p><p>&middot; سُعال، صعوبة في التَّنفس.</p><p>&middot; تفاعلات حساسية، طفح جلدي قد يكون أحمر اللون ومثيرًا للحكة، تساقُط الشعر بشكل طفيف (ثعلبة).</p><p>&middot; تغيُّر في اختبارات الدَّم يشمل الحالات ذات الصلة بالاضطرابات في وظائف الكبد.</p><p>&nbsp;</p><p><strong>شائعة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10 أشخاص):</p><p>&middot; عدوى ناتجة عن الانخفاض في خلايا الدَّم البيضاء،</p><p>&middot; عدوى خطيرة بالدَّم بالإضافة إلى انخفاض في خلايا الدَّم البيضاء (تعفن الدَّم الناتج عن قلة خلايا العدلات)، وهو ما قد يكون مميتًا،</p><p>&middot; انخفاض في عدد خلايا الدَّم البيضاء مصحوب بحُمّى &gt; 38.3 درجة مئوية أو حُمّى تمتد لفترة طويلة &gt; 38 درجة مئوية لأكثر من ساعة (قلة خلايا العَدِلات المصحوب بحُمّى).</p><p>&middot; عُسْر هضم وحموضة، احمرار الجلد، فُواق ودوخة.</p><p>&middot; زيادة التعرُّق واضطرابات الأظافر، تقشُّر الجلد.</p><p>&middot; ألم بالصدر.</p><p>&middot; اضطرابات الرئة وسيلان الأنف.</p><p>&middot; ألم بالمفاصل وألم بالعظام.</p><p>&middot; ألم عند التبوُّل وتغيُّرات في وظائف الكُلى، تغيُّر في معدل تكرار التبوُّل، جفاف.</p><p>&middot; دم في البول والبراز، تورُّم الأوردة، جلطات في الرئة.</p><p>&middot; ارتفاع ضغط الدَّم.</p><p>&middot; اكتئاب وأرق.</p><p>&middot; التهاب الملتحمة، مشاكل بالرؤية.</p><p>&middot; انخفاض مستويات الكالسيوم في الدَّم.</p><p>&middot; السقوط.</p><p>&nbsp;</p><p><strong>غير شائعة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص):</p><p>&middot; عدوى خطيرة بالدَّم (تعفُّن الدَّم)، الأمر الذي قد يكون مميتًا،</p><p>&middot; انسداد أو تورُّم الأمعاء.</p><p>&middot; العصبية.</p><p>&nbsp;</p><p><strong>نادرة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص):</p><p>&middot; فقدان حاسة السمع.</p><p>&middot; تندُّب وزيادة السُّمْك في الرئتين مع صعوبات في التَّنفس، مميتة في بعض الأحيان (مرض الرئة الخلالي).</p><p>&middot; فقدان البصر قصير الأمد القابل للارتداد.</p><p>&middot; نزيف أو كدمات غير متوقعة بسبب تجلُّط الدَّم على نطاق واسع في جميع أنحاء الأوعية الدموية الدقيقة في الجسم (تجلُّط الدَّم داخل الأوعية الدَّموية)، والتي قد تكون مميتة.</p><p>&nbsp;</p><p><strong>نادرة جدًّا</strong> (قد تُؤثر على ما يصل إلى شخص واحد من كل 10000 شخص):</p><p>&middot; مرض كُلوي من أعراضه قلة التبوُّل أو عدم التبوُّل (أعراض الفشل الكُلوي الحاد).</p><p>&middot; اضطرابات الأوعية الدَّموية في الكبد.</p><p>&nbsp;</p><p><strong>معدل التكرار غير معروف</strong> (لا يمكن تقديره من واقع البيانات المتاحة):</p><p>&middot; التهاب الأوعية الدَّموية.</p><p>&middot; تفاعلات مناعية ذاتية تُؤدي إلى انخفاض جميع خطوط خلايا الدَّم (قلة الكريات الشاملة المناعية الذاتية)، قلة الكريات الشاملة.</p><p>&middot; عدوى خطيرة بالدَّم وانخفاض ضغط الدَّم (صدمة تعفُّن الدَّم)، الأمر الذي قد يكون مميتًا.</p><p>&middot; اختلاجات (ارتجاف الجسم بشكل خارج عن السيطرة).</p><p>&middot; تشنُّج الحَلْق مما يُسبب صعوبة في التنفس.</p><p>&middot; تم الإبلاغ عن تعب شديد مع انخفاض عدد خلايا الدَّم الحمراء وضيق التنفس (فقر الدَّم الانحلالي) وحده أو بمصاحبة انخفاض عدد الصفائح الدَّموية ومرض كُلوي من أعراضه قلة التبوُّل أو عدم التبوُّل (أعراض متلازمة انحلال الدَّم اليوريمي) الأمر الذي قد يكون مميتًا.</p><p>&middot; اضطراب النَّظْم القلبي (إطالة فترة QT)، والذي يُمكِن ملاحظته على مخطط كهربية القلب (رسم القلب)، وهو ما قد يكون مميتًا.</p><p>&middot; احتشاء عضلة القلب (نوبة قلبية)، ذبحة صدرية (ألم أو شعور غير مريح في الصدر).</p><p>&middot; ألم وتورُّم عضلي، يصاحبه ضعف، حُمّى، أو بول أحمر مائل إلى البني (أعراض التلف العضلي التي تُسمى انحلال الربيدات)، وهي حالة قد تسبب الوفاة.</p><p>&middot; التهاب المريء (التهاب بطانة المريء -الأنبوب الذي يربط بين الفم ومعدتك- وهو ما يُؤدي إلى ألم وصعوبة في البلع).</p><p>&middot; ألم في البطن، غثيان، قيء مصحوب بدم أو قيء يشبه &quot;البن المطحون&quot;، أو براز داكن اللون/ قطراني (أعراض الإصابة بقُرحة بالجهاز الهضمي مع احتمالية التعرُّض لنزيف أو انثقاب)، وهو ما قد يكون مميتًا.</p><p>&middot; انخفاض تدفُّق الدَّم إلى الأمعاء (إقْفار معوي)، وهي حالة قد تسبب الوفاة.</p><p>&middot; احتمالية للتعرُّض لخطر الإصابة بسرطانات جديدة. تم الإبلاغ عن الإصابة بلوكيميا، شكل من أشكال سرطان الدَّم، في المرضى بعد تناوُل عقار زاليبتين&reg; بمصاحبة بعض الأدوية الأخرى. تحدَّث إلى طبيبك بشأن احتمالية تعرُّضك لاحتمالية مرتفعة لخطر الإصابة بهذا النوع من السرطان عند تناوُل عقار زاليبتين&reg; مع بعض الأدوية الأخرى.</p><p>&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك. ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p>&nbsp;</p><p><strong>يجب تفادي ملامسة عقار زاليبتين&reg; للعينين أو الجلد. إذا حدث أي انسكاب عَرَضي، أخبر الطبيب أو الممرض(ة) فورًا.</strong></p><p>&nbsp;</p><p>قبل الخلط، يجب الاحتفاظ بهذا المُنتَج الدَّوائي في العبوة الكرتونية الخارجية لحمايته من الضوء كما يجب عدم تعريضه للتَّجميد.</p><p>&nbsp;</p><p>لا يُخزَّن في درجة حرارة تتعدى 30 درجة مئوية.</p><p>&nbsp;</p><p>لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة واللاصق بعد كلمة &quot;EXP&quot; يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;</p><p>عند الانتهاء من التَّسريب، سيتم التَّخلص من عقار زاليبتين&reg; بعناية من قِبَل الطبيب أو الممرض(ة).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot; المادة الفعالة هي أوكساليبلاتين.</p><p>&middot; المُكوِّن الآخر هو ماء للحَقْن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>محلول صافٍ وعديم اللون. خالٍ من الجسيمات المرئية.</p><p>يحتوي كل مللي لتر من المحلول على 5 مجم أوكساليبلاتين كمادة فعَّالة. هذا المنتج الدَّوائي هو مادة مُركَّزة؛ لإعداد محلول للتسريب.</p><p>يحتوي كل 10 مللي لتر من المادة المُركَّزة المُخَصصة لإعداد محلول للتَّسريب على 50 مجم أوكساليبلاتين. يحتوي كل 20 مللي لتر من المادة المُركَّزة المُخَصصة لإعداد محلول للتَّسريب على 100 مجم أوكساليبلاتين. يحتوي كل 30 مللي لتر من المادة المُركَّزة المُخَصصة لإعداد محلول للتَّسريب على 150 مجم أوكساليبلاتين. يحتوي كل 40 مللي لتر من المادة المُركَّزة المُخَصصة لإعداد محلول للتَّسريب على&nbsp;200 مجم أوكساليبلاتين. يحتوي كل 50 مللي لتر من المادة المُركَّزة المُخَصصة لإعداد محلول للتَّسريب على 250 مجم أوكساليبلاتين.</p><p>&nbsp;</p><p>أحجام العبوة:</p><p>50 مجم/10 مللي لتر: زجاجة واحدة أو 5 زجاجات أو 10 زجاجات</p><p>100 مجم/20 مللي لتر: زجاجة واحدة</p><p>150 مجم/30 مللي لتر: زجاجة واحدة</p><p>200 مجم/40 مللي لتر: زجاجة واحدة</p><p>250 مجم/50 مللي لتر: زجاجة واحدة</p><p>&nbsp;</p><p>مع أو بدون غلاف بلاستيكي واقٍ (أونكوسيف&reg;).</p><p>&nbsp;</p><p>قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التَّسويق</strong></p><p>شركة هيكسال إيه جي، هولزكيرشن،</p><p>ألمانيا</p><p>&nbsp;</p><p><strong>جهة التَّصنيع</strong></p><p>شركة فاريفا أونتراخ المحدودة ،</p><p>أونتراخ، النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xaliptine 5 mg/ml concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10 ml of concentrate for solution for infusion contain 50 mg of oxaliplatin 
20 ml of concentrate for solution for infusion contain 100 mg of oxaliplatin 
40 ml of concentrate for solution for infusion contain 200 mg of oxaliplatin 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion Clear, colourless liquid

pH: 4.5 – 6.5

Osmolarity: approximately 8 mOsmol/kg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for:</p><p>&nbsp;</p><p>&middot; Adjuvant treatment of stage III (Duke&#39;s C) colon cancer after complete resection of primary tumor</p><p>&middot; Treatment of metastatic colorectal cancer</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medical product used, in conditions that guarantee the integrity of the medical product, the protection of the environment and in particular the protection of the personnel handling the medicinal products, in accordance with the hospital policy. It requires a preparation area&nbsp;</p><p>reserved for this purpose. It is forbidden to smoke, eat or drink in this area (see section 6.6 for detailed information).</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>FOR ADULTS ONLY</p><p>&nbsp;</p><p>The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m&sup2; intravenously repeated every two weeks for 12 cycles (6 months).</p><p>&nbsp;</p><p>The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m&sup2; intravenously repeated every 2 weeks until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Dosage given should be adjusted according to tolerability (see section 4.4).</p><p>&nbsp;</p><p><strong>Oxaliplatin should always be administered before fluoropyrimidines-i.e. 5-fluorouracil (5FU).</strong></p><p>&nbsp;</p><p>Oxaliplatin is administered as a 2- to 6-hour intravenous infusion in 250 to 500 ml of 5% glucose solution (50mg/ml) to give a concentration between 0.2 mg/ml and 0.70 mg/ml; 0.7 mg/ml is the highest concentration in clinical practice for an oxaliplatin dose of 85 mg/m2.</p><p>Oxaliplatin was mainly used in combination with continuous infusion 5-fluorouracil based regimens. For the two-weekly treatment schedule 5-fluorouracil regimens combining bolus and continuous infusion were used.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p>- Renal impairment:</p><p>Oxaliplatin must not be administered in patients with severe renal impairment (see section 4.3 and 5.2).</p><p>In patients with mild or moderate renal impairment, treatment may be initiated at the normally recommended dose (see section 4.4 and 5.2).</p><p>&nbsp;</p><p>- Hepatic impairment:</p><p>In a phase I study including patients with several levels of hepatic impairment, frequency and severity of hepato-biliary disorders appeared to be related to progressive disease and impaired liver function tests at baseline. No specific dose adjustment for patients with abnormal liver function tests was performed during clinical development.</p><p>&nbsp;</p><p>- Elderly patients :</p><p>No increase in severe toxicities was observed when oxaliplatin was used as a single agent or in combination with 5-fluorouracil in patients over the age of 65. In consequence no specific dose adaptation is required for elderly patients.</p><p>&nbsp;</p><p>- Pediatric patients:</p><p>There is no relevant indication for use of oxaliplatin in children. The effectiveness of oxaliplatin single agent in the paediatric populations with solid tumors has not been established (see section 5.1)</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oxaliplatin is administered by intravenous infusion.</p><p>The administration of oxaliplatin does not require hyperhydration.</p><p>Oxaliplatin diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml must be infused via a central venous line or peripheral vein over 2 to 6 hours. Oxaliplatin infusion should always precede that of 5-fluorouracil.</p><p>In the event of extravasation, administration must be discontinued immediately.</p><p>&nbsp;</p><p><u>Instructions for use</u></p><p>Oxaliplatin must be further diluted before use. Only 5% glucose diluent is to be used to dilute the concentrate for solution for infusion. (see section 6.6 ).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oxaliplatin is contraindicated in patients who

· have a known history of hypersensitivity to the active substance or to any of the excipients.

· are breast feeding.

· have myelosuppression prior to starting first course, as evidenced by baseline neutrophils

< 2 x 109/l and/or platelet count of < 100 x 109/l .

· have a peripheral sensory neuropathy with functional impairment prior to first course.

· have a severely impaired renal function (creatinine clearance less than 30 ml/min) (see Section 5.2).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oxaliplatin should only be used in specialised departments of oncology and should be administered under the supervision of an experienced oncologist.</p><p><u><em>Renal impairment</em></u></p><p>Patients with mild to moderate renal impairment should be closely monitored for adverse reactions and dose adjusted according to toxicity (see section 5.2).</p><p>&nbsp;</p><p><u><em>Hypersensitivity reactions</em></u></p><p>Special surveillance should be ensured for patients with a history of allergic manifestations to other products containing platinum. In case of anaphylactic manifestations the infusion should be interrupted immediately and an appropriate symptomatic treatment started. Re-administration of oxaliplatin to such patients is contraindicated. Cross reactions, sometimes fatal, have been reported with all platinum compounds.</p><p>&nbsp;</p><p>In case of oxaliplatin extravasation, the infusion must be stopped immediately and usual local symptomatic treatment initiated.</p><p><em><u>Neurological Symptoms</u></em></p><p>Neurological toxicity of oxaliplatin should be carefully monitored, especially if co-administered with other medications with specific neurological toxicity. A neurological examination should be performed before each administration and periodically thereafter.</p><p>&nbsp;</p><p>For patients who develop acute laryngopharyngeal dysaesthesia (see section 4.8) during or within several hours after a 2-hour infusion, the subsequent oxaliplatin infusion must be administered over 6 hours.</p><p>&nbsp;</p><p><u><em>Peripheral neuropathy</em></u></p><p>If neurological symptoms (paraesthesia, dysaesthesia) occur, the following recommended oxaliplatin dosage adjustment should be based on the duration and severity of these symptoms:</p><p>&middot; If symptoms last longer than seven days and are troublesome, the subsequent oxaliplatin dose should be reduced from 85 to 65 mg/m2 (metastatic setting) or 75 mg/m2 (adjuvant setting).</p><p>&middot; If paraesthesia without functional impairment persists until the next cycle, the subsequent oxaliplatin dose should be reduced from 85 to 65 mg/m2 (metastatic setting) or 75 mg/m2 (adjuvant setting).</p><p>&middot; If paraesthesia with functional impairment persists until the next cycle, oxaliplatin should be discontinued.</p><p>&middot; If these symptoms improve following discontinuation of oxaliplatin therapy, resumption of therapy may be considered.</p><p>&nbsp;</p><p>Patients should be informed about the possibility of persistent symptoms of peripheral sensory neuropathy after the end of the treatment. Localised moderate paraesthesia or paraesthesia that may interfere with functional activities can persist after up to 3 years following treatment cessation in the adjuvant setting.</p><p>&nbsp;</p><p><u><em>Reversible Posterior Leukoencephalopathy Syndrome (RPLS)</em></u></p><p>Cases of Reversible Posterior Leukoencephalopathy Syndrome (RPLS, also known as PRES, Posterior Reversible Encephalopathy Syndrome) have been reported in patients receiving oxaliplatin in combination chemotherapy. RPLS is a rare, reversible, rapidly evolving neurological condition, which can include seizure, hypertension, headache, confusion, blindness, and other visual and neurological disturbances (see section 4.8).</p><p>Diagnosis of RPLS is based upon confirmation by brain imaging, preferably MRI (Magnetic Resonance Imaging).</p><p>&nbsp;</p><p><em><u>Nausea, vomiting, diarrhoea, dehydration, and haematological changes</u></em></p><p>Gastrointestinal toxicity of oxaliplatin, i.e. symptoms such as nausea and vomiting, requires prophylactic and/or therapeutic use of antiemetics (see section 4.8).</p><p>&nbsp;</p><p>Dehydration, paralytic ileus, intestinal obstruction, hypokalemia, metabolic acidosis and renal impairment may be caused by severe diarrhoea/emesis particularly when combining oxaliplatin with 5-fluorouracil (5-FU).</p><p>Cases of intestinal ischaemia, including fatal outcomes, have been reported with oxaliplatin treatment. In case of intestinal ischaemia, oxaliplatin treatment should be discontinued and appropriate measures initiated (see section 4.8).</p><p>If haematological toxicity occurs (neutrophils &lt; 1.5 x 109/l or platelets &lt; 50 x 109/l), administration of the next course of therapy should be postponed until haematological values return to acceptable levels.</p><p>&nbsp;</p><p>A full blood count with white cell differential should be performed prior to start therapy and before each subsequent course.</p><p>&nbsp;</p><p>Myelosuppressive effects may be additive to those of concomitant chemotherapy. Patient with severe and persistent myelosuppression are at high risk of infectious complications. Sepsis, neutropenic sepsis and septic shock have been reported in patients treated with oxaliplatin including fatal outcomes (see section 4.8.). If any of these events occurs, oxaliplatin should be discontinued.</p><p>&nbsp;</p><p>Patients must be adequately informed about the risk of diarrhoea/emesis, mucositis/stomatitis and neutropenia following oxaliplatin and 5-fluorouracil (5-FU) administration so they can urgently contact their treating physician for appropriate management.</p><p>&nbsp;</p><p>If mucositis/stomatitis occurs with or without neutropenia, the next treatment should be delayed until</p><p>recovery from mucositis/stomatitis to grade I or less and/or until the neutrophil count is &ge; 1.5 x 109/l.</p><p>&nbsp;</p><p>For oxaliplatin combined with 5-fluorouracil (5-FU) (with or without folinic acid), the usual dose adjustments for 5-fluorouracil associated toxicities should apply.</p><p>&nbsp;</p><p>If grade 4 diarrhoea, grade 3-4 neutropenia (neutrophils &lt; 1.0 x 109/l), febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection with an absolute neutrophil count &lt;1.0 x 109/l, a single temperature of &gt;38.3&deg;C or a sustained temperature of &gt;38&deg;C for more than one hour), or grade 3-4 thrombocytopenia (platelets &lt; 50 x 109/l) occur, the dose of oxaliplatin should be reduced from 85 mg/m2 to 65 mg/m2 (metastatic setting) or 75 mg/m2 (adjuvant setting), in addition to any 5-fluorouracil (5-FU) dose reductions required.</p><p>&nbsp;</p><p><em><u>Pulmonary</u></em></p><p>In cases of unexplained respiratory symptoms such as non-productive cough, dyspnoea, crackles or radiological pulmonary infiltrates, oxaliplatin should be discontinued until further pulmonary investigations exclude an interstitial lung disease or pulmonary fibrosis (see section 4.8).</p><p>&nbsp;</p><p><em><u>Blood disorders</u></em></p><p>Haemolytic-uraemic syndrome (HUS) is a life-threatening side effect (frequency not known). Oxaliplatin should be discontinued at the first signs of any evidence of microangiopathic haemolytic anaemia, such as rapidly falling haemoglobin with concomitant thrombocytopenia, elevation of serum bilirubin, serum creatinine, blood urea nitrogen, or LDH. Renal failure may not be reversible with discontinuation of therapy and dialysis may be required.</p><p>Disseminated intravascular coagulation (DIC), including fatal outcomes, has been reported in association with oxaliplatin treatment. If DIC is present, oxaliplatin treatment should be discontinued and appropriate treatment should be administered (see section 4.8). Caution should be exercised in patients with disorders related to DIC, such as infections, sepsis etc.</p><p>&nbsp;</p><p><em><u>QT prolongation</u></em></p><p>QT prolongation may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes, which can be fatal (see section 4.8). The QT interval should be closely monitored on a regular basis before and after administration of oxaliplatin. Caution should be exercised in patients with a history or a predisposition for prolongation of QT, those who are taking medicinal products known to prolong QT interval, and those with electrolyte disturbances such as hypokalaemia, hypocalcaemia, or hypomagnesaemia. In case of QT prolongation, oxaliplatin treatment should be discontinued (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p><em><u>Rhabdomyolysis</u></em></p><p>&nbsp;</p><p>Rhabdomyolysis has been reported in patients treated with oxaliplatin, including fatal outcomes. In case of muscle pain and swelling, in combination with weakness, fever or darkened urine, oxaliplatin treatment should be discontinued. If rhabdomyolysis is confirmed, appropriate measures should be taken. Caution is recommended if medicinal products associated with rhabdomyolysis are administered concomitantly with oxaliplatin (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p><em><u>Gastrointestinal ulcer/gastrointestinal haemorrhage and perforation</u></em></p><p>Oxaliplatin treatment can cause gastrointestinal ulcer and potential complications, such as gastrointestinal haemorrhage and perforation, which can be fatal. In case of gastrointestinal ulcer, oxaliplatin treatment should be discontinued and appropriate measures taken (see section 4.8).</p><p>&nbsp;</p><p><em><u>Hepatic</u></em></p><p>In case of abnormal liver function test results or portal hypertension, which does not obviously result from liver metastases, very rare cases of drug-induced hepatic vascular disorders should be considered.</p><p>&nbsp;</p><p><em><u>Pregnancy</u></em></p><p>For use in pregnant women, see section 4.6.</p><p>&nbsp;</p><p><em><u>Fertility</u></em></p><p>Genotoxic effects were observed with oxaliplatin in preclinical studies. Therefore male patients treated with oxaliplatin are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because oxaliplatin may have an anti-fertility effect which could be irreversible.</p><p>&nbsp;</p><p>Women should not become pregnant during treatment with oxaliplatin and should use an effective method of contraception (see section 4.6).</p><p>&nbsp;</p><p>Peritoneal haemorrhage may occur when oxaliplatin is administered by intraperitoneal route (off- label route of administration).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients who have received a single dose of 85 mg/m2 of oxaliplatin, immediately before administration of 5-fluorouracil (5-FU), no change in plasma levels of 5-fluorouracil (5-FU) has been observed.</p><p>In vitro, no significant displacement of oxaliplatin binding to plasma proteins has been observed with the following agents: erythromycin, salicylates, granisetron, paclitaxel, and sodium valproate.</p><p>&nbsp;</p><p>Caution is advised when oxaliplatin treatment is co-administered with other medicinal products known to cause QT interval prolongation. In case of combination with such medicinal products, the QT interval should be closely monitored (see section 4.4). Caution is advised when oxaliplatin treatment is administered concomitantly with other medicinal products known to be associated with rhabdomyolysis (see section 4.4)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>To date there is no available information on safety of use in pregnant women. In animal studies, reproductive toxicity was observed. Consequently, oxaliplatin is not recommended during pregnancy and in women of childbearing potential not using contraceptive measures.</p><p>&nbsp;</p><p>The use of oxaliplatin should only be considered after suitably appraising the patient of the risk to the foetus and with the patient&#39;s consent.</p><p>&nbsp;</p><p>Appropriate contraceptive measures must be taken during and after cessation of therapy during 4 months for women.</p><p>&nbsp;</p><p><u>Breast feeding</u></p><p>Excretion in breast milk has not been studied. Breast-feeding is contraindicated during oxaliplatin therapy.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Oxaliplatin may have an anti-fertility effect (see section 4.4 )</p><p>&nbsp;</p><p>Due to the potential genotoxic effects of oxaliplatin, appropriate contraceptive measures must be taken during and after cessation of therapy during 4 months for women and 6 months for men</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>However, oxaliplatin treatment resulting in an increased risk of dizziness, nausea and vomiting and other neurological symptoms that affect gait and balance may lead to a minor or moderate influence on the ability to drive and use machines.</p><p>Vision abnormalities, in particular transient vision loss (reversible following therapy discontinuation), may affect patients&#39; ability to drive and use machines. Therefore, patients should be warned of the potential effect of these events on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p>The most frequent adverse events of oxaliplatin in combination with 5-fluorouracil and folinic acid (5- FU and FA) were of gastrointestinal (diarrhoea, nausea, vomiting and mucositis), haematological (neutropenia, thrombocytopenia) and neurological (acute and dose cumulative peripheral sensory neuropathy) nature.</p><p>Overall, these adverse events were more frequent and severe when 5-FU/FA was administered in combination with oxaliplatin compared to 5-FU/FA alone.</p><p>&nbsp;</p><p>Tabulated list of adverse reactions</p><p>The frequencies reported in the table below are derived from clinical trials in the metastatic and adjuvant settings (having included 416 and 1108 patients respectively in the oxaliplatin + 5-FU/FA treatment arms) and from post marketing experience.</p><p>Frequencies in this table are defined using the following convention: very common (&ge; 1/10) common (&ge; 1/100 &lt; 1/10), uncommon (&ge; 1/1,000 &lt; 1/100), rare (&ge; 1/10,000 &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>Further details are given following this table.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>MedDRA Very common Common Uncommon Rare Very rare Not known</strong></p><p><strong>classification</strong></p><p><strong>Infections and infestations*</strong> - Infection - Rhinitis - Upper respiratory tract infection - neutropenic sepsis+ - Sepsis+</p><p><strong>Blood and lymphatic system disorders *</strong> - Anemia - Neutropenia - Thrombo- cytopenia - Leukopenia - Lymphopenia - Febrile neutropenia - Haemolytic anemia - Immunoallergi c thrombocytope nia Autoimmune pancytopenia</p><p><strong>Immune system disorders* </strong>- Allergy/allergic reaction++</p><p><strong>Metabolism and nutrition disorders</strong> - Anorexia - Hyperglycemia, - Hypokalaemia - Hypernatraemia - Dehydration, - Hypocalcae mia - Metabolic acidosis</p><p><strong>Psychiatric disorders -</strong> Depression - Insomnia - Nervousness</p><p><strong>Nervous system disorders * - </strong>Peripheral sensory neuropathy - Headache - Sensory disturbance - Dysgeusia - Dizziness - Motor neuritis - Meningism - Dysarthria, - Reversible Posterior Leukoencepha lopathy syndrome (RPLS - also known as PRES)**</p><p><strong>Eye disorders</strong> - Conjunctiviti s - Visual disturbance - Visual acuity reduced transiently - visual field disturbances - optic neuritis - transient vision loss (reversible following therapy discontinuatio n)</p><p><strong>Ear and labyrinth disorders</strong> Ototoxicity Deafness</p><p><strong>Vascular disorders -</strong> Haemorrhag e - Flushing - Deep vein thrombosis - Hypertensio n</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong> - Dyspnoea - Cough - Epistaxis - Hiccups - Pulmonary embolism - Interstitial lung disease, sometimes fatal - Pulmonary fibrosis **</p><p><strong>Gastrointestinal disorders*</strong> - Diarrhea - Nausea - Vomiting - Stomatitis / Mucositis - Abdominal pain - Constipation - Dyspepsia - Gastroesoph ageal reflux - Gastrointesti nal haemorrhage - Rectal haemorrhage - Ileus, - intestinal obstruction - Colitis including Clostridium difficile diarrhea - pancreatitis</p><p><strong>Hepato-biliary disorders </strong>Liver sinusoidal obstruction syndrome (see below)</p><p><strong>Skin and subcutaneous tissue disorders</strong> - Skin disorder - Alopecia - Skin exfoliation (i.e. hand and foot syndrome) - Rash erythematous, - Rash - Hyperhidrosis - Nail disorder - Hyper- sensitivity vasculitis</p><p>&nbsp;</p><p><strong>Musculoskeletal system, connective tissue and bone disorders</strong> - Back pain - Arthralgia - Bone pain</p><p><strong>Renal and urinary disorders</strong> - Haematuria - Dysuria - micturition frequency abnormal</p><p><strong>General disorders and administration site conditions</strong> - Fever+++ - Injection site reaction++++ - Fatigue - Asthenia - Pain</p><p><strong>Investigations</strong> - Blood alkaline phosphatase increase - Blood bilirubin increase - Blood lactate dehydrogenase (LDH) increase - Hepatic enzymes increase - Blood creatinine increase - Weight decrease (metastatic setting)</p><p>- Weight increase (adjuvant setting)</p><p><strong>Injury, poisoning and procedural complications </strong>Fall;</p><p>&nbsp;</p><p>See detailed information in the section below</p><p>** See section 4.4.</p><p>&nbsp;</p><p>+ Common neutropenic sepsis, including fataloutcomes.</p><p>++ Very common allergies/allergic reactions, occurring mainly during infusion, sometimes fatal. Common allergic reactions include skin rash, particularly urticaria, conjunctivitis, and rhinitis. Common anaphylactic or anaphylactoid reactions include bronchospasm, angioedema, hypotension, sensation of chest pain and anaphylactic shock. Delayed hypersensitivity has also been reported with oxaliplatin hours or even days after the infusion.</p><p>+++ Very common fever, rigors (tremors), either from infection (with or without febrile neutropenia) or possibly from immunologicalmechanism.</p><p>++++ Injection site reactions including local pain, redness, swelling and thrombosis have been reported. Extravasation may also result in local pain and inflammation which may be severe and lead to complications including necrosis, especially when oxaliplatin is infused through a peripheral vein (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>Description of selected adverse reactions</p><p>&nbsp;</p><p><u>Blood and lymphatic system disorders</u></p><p>&nbsp;</p><p><strong>Incidence by patient (%) and by grade</strong></p><p>Oxaliplatin/5 FU/FA, 85 mg/m2 every 2 weeks Treatment of metastases Adjuvant therapy All grades Grade 3 Grade 4 All grades Grade 3 Grade 4</p><p>Anaemia 82.2 3 &lt;1 75.6 0.7 0.1</p><p>Neutropenia 71.4 28 14 78.9 28.8 12.3</p><p>Thrombocytopenia 71.6 4 &lt;1 77.4 1.5 0.2</p><p>Febrile neutropenia 5.0 3.6 1.4 0.7 0.7 0.0</p><p>&nbsp;</p><p>Rare (&gt;1/10,000 to &lt;1/1,000)</p><p>Disseminated intravascular coagulation (DIC), including fatal outcomes (see section 4.4).</p><p>&nbsp;</p><p>P<u>ostmarketing experience with frequency not known:</u></p><p>Hemolytic uremic syndrome</p><p>Autoimmune pancytopenia Pancytopenia</p><p>Secondary leukemia</p><p>&nbsp;</p><p><strong>Infections and infestations Incidence by patient (%)</strong></p><p><strong>Oxaliplatin and 5-FU/FA 85 Metastatic Setting Adjuvant Setting</strong></p><p><strong>mg/m2 Every 2 weeks All grades All grades</strong></p><p>Sepsis (including sepsis and</p><p>neutropenic sepsis) 1.5 1.7</p><p>&nbsp;</p><p><em><u>Post-marketing experience with frequency not known</u></em></p><p>Septic shock, including fatal outcomes.</p><p>&nbsp;</p><p><u>Immune system disorders:</u></p><p>&nbsp;</p><p><strong>Incidence of allergic reactions by patient (%) and by grade</strong></p><p>&nbsp;</p><p>Oxaliplatin/5 FU/FA, 85mg/m2 every 2 weeks Treatment of metastases Adjuvant therapy All grades Grade 3 Grade 4 All grades Grade 3 Grade 4</p><p>Allergic</p><p>reactions/Allergy 9.1 1 &lt; 1 10.3 2.3 0.6</p><p>&nbsp;</p><p><u>Nervous system disorders:</u></p><p>&nbsp;</p><p>The dose limiting toxicity of oxaliplatin is neurological. It involves a sensory peripheral neuropathy characterised by dysaesthesia and/or paraesthesia of the extremities with or without cramps, often triggered by the cold. These symptoms occur in up to 95% of patients treated. The duration of these symptoms, which usually regress between courses of treatment, increases with the number of treatment cycles.</p><p>The onset of pain and/or functional disorders is an indication for dose adjustments or even treatment discontinuation, depending on the duration of these symptoms (see section 4.4).</p><p>These functional disorders include difficulties in executing delicate movements and are a possible consequence of sensory impairment. The risk of occurrence of persistent symptoms for a cumulative dose of 850mg/m2 (10 cycles) is approximately 10% and 20% for a cumulative dose of 1,020 mg/m2 (12 cycles).</p><p>In the majority of the cases, the neurological signs and symptoms improved or totally recovered when treatment was discontinued. In the adjuvant setting of colon cancer, 6 months after treatment cessation, 87% of patients had no or mild symptoms. After up to 3 years of follow-up, about 3% of patients presented either with persistent localised paraesthesia of moderate intensity (2.3%) or with paraesthesia that may interfere with functional activities (0.5%).</p><p>Acute neurosensory manifestations (see section 5.3) have been reported. They start within hours of administration and often occur on exposure to cold. They usually present as transient paraesthesia, dysaesthesia and hypoesthesia. An acute syndrome of pharyngolaryngeal dysaesthesia occurs in 1% and 2% of patients and is characterised by subjective sensations of dysphagia or dyspnoea/feeling of suffocation, without any objective evidence of respiratory distress (no cyanosis or hypoxia) or of laryngospasm or bronchospasm (no stridor or wheezing). Although antihistamines and bronchodilators have been administered in such cases, the symptoms were rapidly reversible even in the absence of treatment. Prolongation of the infusion helps to reduce the incidence of this syndrom (see section 4.4).</p><p>Occasionally other symptoms that have been observed include jaw spasm/muscle spasms/muscle contractions-involuntary/muscle twitching/myoclonus, coordination abnormal /gait abnormal/ataxia/ balance disorders, throat or chest tightness/pressure/discomfort/pain. In addition, cranial nerve dysfunctions may be associated with the above mentioned events, or also occur as an isolated event such as ptosis, diplopia, aphonia, dysphonia, hoarseness, sometimes described as vocal cord paralysis, abnormal tongue sensation or dysarthria, sometimes described as aphasia, trigeminal neuralgia, facial pain, eye pain, decrease in visual acuity, visual field disorders.</p><p>Other neurological symptoms such as dysarthria, loss of deep tendon reflex and Lhermitte&#39;s sign were reported during treatment with oxaliplatin. Isolated cases of optic neuritis have been reported.</p><p>&nbsp;</p><p><u>Postmarketing experience with frequency not known:</u></p><p>Convulsion</p><p>Ischemic or haemorrhagic cerebrovascular disorder</p><p>&nbsp;</p><p><em>Cardiac disorders</em></p><p><u><em>Post-marketing experience with frequency not known</em></u></p><p>QT prolongation, which may lead to ventricular arrhythmias including Torsade de Pointes, which may be fatal (see section 4.4).</p><p>Acute coronary syndrome (including myocardial infarction and coronary arteriospasm and angina pectoris in patients treated with Oxaliplatin in combination with 5-FU and bevacizumab)</p><p>&nbsp;</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>&nbsp;</p><p><u><em>Post-marketing experience with frequency not known</em></u></p><p>Laryngospasm</p><p>Pneumonia and bronchopneumonia, including fatal outcomes</p><p>&nbsp;</p><p><u>Gastrointestinal disorders</u></p><p><strong>Incidence by patient (%) and by grade</strong></p><p>&nbsp;</p><p>Oxaliplatin/5 FU/FA, 85 mg/m2 every 2 weeks Treatment of metastases Adjuvant therapy All grades Grade 3 Grade 4 All grades Grade 3 Grade 4</p><p>Nausea 69.9 8 &lt; 1 73.7 4.8 0.3</p><p>Diarrhoea 60.8 9 2 56.3 8.3 2.5</p><p>Vomiting 49.0 6 1 47.2 5.3 0.5</p><p>Mucositis / Stomatitis 39.9 4 &lt; 1 42.1 2.8 0.1</p><p>&nbsp;</p><p>Prophylaxis and/or treatment with potent antiemetic agents is indicated.</p><p>Dehydration, paralytic ileus, intestinal obstruction, hypokalemia, metabolic acidosis and renal impairment may be caused by severe diarrhoea/emesis particularly when combining oxaliplatin with 5-fluorouracil (5-FU) (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Postmarketing experience with frequency not known</u></em></p><p>Intestinal ischaemia, including fatal outcomes (see section 4.4). Gastrointestinal ulcer and perforation, which can be fatal (see section 4.4). Oesophagitis</p><p>&nbsp;</p><p><em>Hepatobiliary disorders:</em></p><p>Very rare (&lt; 1/10,000): Hepatic sinusoidal obstruction syndrome, also known as veno-occlusive liver disease, or pathological manifestations related to such liver disorder, including peliosis hepatis, nodular regenerative hyperplasia and perisinusoidal fibrosis. Clinical manifestations may be portal hypertension and/or increased transaminases.</p><p>&nbsp;</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p>&nbsp;</p><p><u>Post-marketing experience with frequency not known</u></p><p>Rhabdomyolysis, including fatal outcomes (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Renal and urinary disorders </em></p><p><em>Very rare ( 1/10,000):</em></p><p>Acute tubular necrosis, acute interstitial nephritis and acute renal failure.</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders</em></p><p><em><u>Post-marketing experience with frequency not known</u></em></p><p>Hypersensitivity vasculitis</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>There is no known antidote to oxaliplatin. In cases of overdose, exacerbation of adverse events can be expected.</p><p>&nbsp;</p><p><em>Management</em></p><p>Monitoring of haematological parameters should be initiated and symptomatic treatment given</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antineoplastic agents, platinum compounds ATC-Code: L01XA03</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Oxaliplatin is an antineoplastic active substance belonging to a new class of platinum-based compounds in which the platinum atom is complexed with 1,2-diaminocyclohexane (&ldquo;DACH&rdquo;) and an oxalate group.</p><p>&nbsp;</p><p>Oxaliplatin is a single enantiomer, the Cis-[oxalato(trans-l-1,2- DACH) platinum].</p><p>&nbsp;</p><p>Oxaliplatin exhibits a wide spectrum of both in vitro cytotoxicity and in vivo antitumour activity in a variety of tumour model systems including human colorectal cancer models. Oxaliplatin also demonstrates in vitro and in vivo activity in various cisplatin resistant models.</p><p>&nbsp;</p><p>A synergistic cytotoxic action has been observed in combination with 5-fluorouracil both in vitro and in vivo.</p><p>Studies on the mechanism of action of oxaliplatin, although not completely elucidated, show that the aqua-derivatives resulting from the biotransformation of oxaliplatin, interact with DNA to form both inter and intra-strand cross-links, resulting in the disruption of DNA synthesis leading to cytotoxic and antitumour effects.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>In patients with metastatic colorectal cancer, the efficacy of oxaliplatin (85mg/m2 repeated every two weeks) combined with 5-fluorouracil/folinic acid (5-FU/FA) is reported in three clinical studies:</p><p>&nbsp;</p><p>- In front-line treatment, a 2-arm comparative phase III study (de Gramont, A et al., 2000) randomised 420 patients either to 5-FU/FA alone (LV5FU2, N=210) or the combination of oxaliplatin with 5-FU/FA (FOLFOX4, N=210).</p><p>&nbsp;</p><p>- In pretreated patients, a comparative three arms phase III study (Rothenberg, ML et al., 2003) randomised 821 patients refractory to an irinotecan (CPT-11) + 5-FU/FA combination either to 5- FU/FA alone (LV5FU2, N=275), oxaliplatin single agent (N=275), or combination of oxaliplatin with 5-FU/FA (FOLFOX4, N=271).</p><p>&nbsp;</p><p>- Finally, an uncontrolled phase II study (Andr&eacute;, T et al., 1999) included patients refractory to 5- FU/FA alone, that were treated with the oxaliplatin and 5-FU/FA combination (FOLFOX4, N=57)</p><p>&nbsp;</p><p>The two randomised clinical trials in front-line therapy (de Gramont, A et al.) and in pretreated patients (Rothenberg ML et al.), demonstrated a significantly higher response rate and a prolonged progression free survival (PFS) / time to progression (TTP) as compared to treatment with 5-FU/FA alone. In the study of Rothenberg et al. performed in refractory pretreated patients, the difference in median overall survival (OS) between the combination of oxaliplatin and 5-FU/FA versus 5-FU/FA did not reach statistical significance.</p><p>&nbsp;</p><p>Response rate under FOLFOX4 versus LV5FU2</p><p>Response rate, % (95% CI) independent radiological review ITT analysis LV5FU2 FOLFOX4 Oxaliplatin Single agent</p><p>22 49 NA*</p><p>Front-line treatment (16-27) (42-56)</p><p>(de Gramont, A et al., 2000) P value = 0.0001</p><p>Response assessment every 8</p><p>weeks</p><p>Pretreated patients 0.7 11.1 1.1</p><p>(Rothenberg, ML et al., 2003) (0.0-2.7) (7.6-15.5) (0.2-3.2)</p><p>(refractory to CPT-11 + 5-FU/FA) Response assessment every 6 weeks P value &lt; 0.0001</p><p>NA* 23 NA*</p><p>Pretreated patients (13-36)</p><p>(Andr&eacute;, T et al., 1999)</p><p>(refractory to 5-FU/FA)</p><p>Response assessment every 12</p><p>weeks</p><p>* NA: Not applicable.</p><p>&nbsp;</p><p>Median Progression Free Survival (PFS) / Median Time to Progression (TTP) FOLFOX4 versus LV5FU2</p><p>Median PFS/TTP, Months (95% CI) independent radiological review ITT analysis LV5FU2 FOLFOX4 Oxaliplatin Single agent</p><p>6.0 8.2 NA*</p><p>Front-line treatment (5.5-6.5) (7.2-8.8)</p><p>(de Gramont, A et al., 2000) Log-rank P value = 0.0003</p><p>(PFS)</p><p>Pretreated patients</p><p>(Rothenberg, ML et al., 2003) 2.6 5.3 2.1</p><p>(TTP) (1.8-2.9) (4.7-6.1) (1.6-2.7)</p><p>(refractory to Log-rank P value &lt; 0.0001</p><p>CPT-11 + 5-FU/FA)</p><p>(Pretreated patients</p><p>(Andr&eacute;, T et al., 1999) NA* 5.1 NA*</p><p>(refractory to 5-FU/FA) (3.1-5.7)</p><p>* NA: Not applicable.</p><p>Median Overall Survival (OS) under FOLFOX4 versus LV5FU2</p><p>Median OS, months (95% CI) ITT analysis LV5FU2 FOLFOX4 Oxaliplatin Single agent</p><p>Front-line treatment</p><p>(de Gramont, A et al., 2000) 14.7 (13.0-18.2) 16.2 (14.7-18.2) NA* Log-rank P value = 0.12</p><p>Pretreated patients</p><p>(Rothenberg, ML et al., 2003)</p><p>(TTP)</p><p>(refractory to</p><p>CPT-11 + 5-FU/FA) 8.8 (7.3-9.3) 9.9 (9.1-10.5) 8.1 (7.2-8.7) Log-rank P value = 0.09</p><p>Pretreated patients</p><p>(Andr&eacute;, T et al., 1999)</p><p>(refractory to 5-FU/FA) NA* 10.8 (9.3-12.8) NA*</p><p>* NA: Not applicable.</p><p>&nbsp;</p><p>In pretreated patients (Rothenberg, ML et al., 2003), who were symptomatic at baseline, a higher proportion of those treated with oxaliplatin and 5-FU/FA experienced a significant improvement of</p><p>their disease-related symptoms compared to those treated with 5-FU/FA alone (27.7 % vs 14.6 %, p = 0.0033).</p><p>&nbsp;</p><p>In non pretreated patients (de Gramont, A et al., 2000), no statistically significant difference between the two treatment groups was found for any of the quality of life dimensions. However, the quality of life scores were generally better in the control arm for measurement of global health status and pain and worse in the oxaliplatin arm for nausea and vomiting.</p><p>&nbsp;</p><p>In the adjuvant setting, the MOSAIC comparative phase III study randomised 2246 patients (899 stage II / Duke&#39;s B2 and 1347 stage III / Duke&#39;s C) further to complete resection of the primary tumor of colon cancer either to 5-FU/FA alone (LV5FU2, N=1123 (B2 / C = 448 / 675) or to combination of oxaliplatin and 5-FU/FA (FOLFOX4, N=1123 (B2 / C) = 451 / 672).</p><p>&nbsp;</p><p>MOSAIC-3-year disease free survival (ITT analysis)* for the overall population</p><p>Treatment arm LV5FU2 FOLFOX4</p><p>Percent 3-year disease free survival</p><p>(95% CI) 73.3 (70.6-75.9) 78.7 (76.2-81.1)</p><p>Hazard ratio (95% CI) 0.76 (0.64-0.89)</p><p>Stratified log rank test P = 0.0008</p><p>* median follow up 44.2 months (all patients followed for at least 3 years)</p><p>&nbsp;</p><p>The study demonstrated an overall significant advantage in 3-year disease free survival for the oxaliplatin and 5-FU/FA combination (FOLFOX4) over 5-FU/FA alone (LV5FU2).</p><p>&nbsp;</p><p>&nbsp;</p><p>MOSAIC-3-year Disease Free Survival (ITT analysis)* according to Stage of Disease</p><p>Patient stage Stage II (Duke&#39;s B2) Stage III (Duke&#39;s C)</p><p>Treatment arm LV5FU2 FOLFOX4 LV5FU2 FOLFOX4</p><p>Percent 3-year disease free survival</p><p>(95% CI) 84.3 (80.9-87.7) 87.4 (84.3-90.5) 65.8 (62.2-69.5) 72.8 (69.4-76.2)</p><p>Hazard ratio (95% CI) 0.79 (0.57-1.09) 0.75 (0.62-0.90)</p><p>Stratified log rank test P = 0.151 P = 0.002</p><p>* median follow up 44.2 months (all patients followed for at least 3 years)</p><p>&nbsp;</p><p>Overall Survival (ITT analysis):</p><p>&nbsp;</p><p>At time of the analysis of the 3-year disease free survival, which was the primary endpoint of the MOSAIC trial, 85.1 % of the patients were still alive in the FOLFOX4 arm versus 83.8 % in the LV5FU2 arm. This translated into an overall reduction in mortality risk of 10 % in favour of FOLFOX4 not reaching statistical significance (hazard ratio = 0.90). The figures were 92.2 % versus</p><p>92.4 % in the stage II (Duke&#39;s B2) sub-population (hazard ratio = 1.01) and 80.4 % versus 78.1 % in the stage III (Duke&#39;s C) sub-population (hazard ratio = 0.87), for FOLFOX4 and LV5FU2, respectively.</p><p>&nbsp;</p><p><u><strong>Paediatric population</strong></u></p><p>Oxaliplatin single agent has been evaluated in pediatric population in 2 Phase I (69 patients) and 2 Phase II (166 patients) studies. A total of 235 pediatric patients (7 months-22 years of age) with solid tumors have been treated. The effectiveness of oxaliplatin single agent in the pediatric populations treated has not been established. Accrual in both Phase II studies was stopped for lack of tumor response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adsorption and distribution</u></p><p>&nbsp;</p><p>The pharmacokinetics of individual active compounds have not been determined. The pharmacokinetics of ultrafiltrable platinum, representing a mixture of all unbound, active and inactive platinum species, following a two-hour infusion of oxaliplatin at 130 mg/m2 every three weeks for 1 to 5 cycles and oxaliplatin at 85 mg/m2 every two weeks for 1 to 3 cycles are as follows:</p><p>&nbsp;</p><p>Summary of Platinum Pharmacokinetic Parameter Estimates in Ultrafiltrate Following Multiple Doses of Oxaliplatin at 85 mg/m2 Every Two Weeks or at 130 mg/m2 Every Three Weeks</p><p>Dose Cmax AUC0-48 AUC t1/2&alpha; t1/2&beta; t1/2&gamma; Vss CL</p><p>&mu;g/ml &mu;g * h /ml &mu;g * h /ml h h h l l / h</p><p>85 mg/m2</p><p>&nbsp;</p><p>Mean 0.814 4.19 4.68 0.43 16.8 391 440 17.4</p><p>SD 0.193 0.647 1.40 0.35 5.74 406 199 6.35</p><p>130 mg/m2</p><p>&nbsp;</p><p>Mean 1.21 8.20 11.9 0.28 16.3 273 582 10.1</p><p>SD 0.10 2.40 4.60 0.06 2.90 19.0 261 3.07</p><p>Mean AUC0-48 and Cmax values were determined on Cycle 3 (85 mg/m2) or Cycle 5 (130 mg/m2). Mean AUC, Vss , CL, and CLR0-48 values were determined on Cycle 1.</p><p>Cend, Cmax, AUC, AUC0-48, Vss and CL values were determined by non-compartmental analysis. t1/2&alpha;, t1/2&beta;, t1/2&gamma; were determined by compartmental analysis (Cycles 1-3 combined).</p><p>&nbsp;</p><p>At the end of a 2-hour infusion, 15 % of the administered platinum is present in the systemic circulation, the remaining 85 % being rapidly distributed into tissues or eliminated in the urine. Irreversible binding to red blood cells and plasma, results in half-lives in these matrices that are close to the natural turnover of red blood cells and serum albumin. No accumulation was observed in plasma ultrafiltrate following 85 mg/m2 every two weeks or 130 mg/m2 every three weeks and steady state was attained by Cycle one in this matrix. Inter- and intra-subject variability is generally low.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Biotransformation in vitro is considered to be the result of non-enzymatic degradation and there is no evidence of cytochrome P450-mediated metabolism of the diaminocyclohexane (DACH) ring.</p><p>&nbsp;</p><p>Oxaliplatin undergoes extensive biotransformation in patients, and no intact active substance was detectable in plasma ultrafiltrate at the end of a 2h-infusion. Several cytotoxic biotransformation&nbsp;</p><p>products including the monochloro-, dichloro- and diaquo-DACH platinum species have been identified in the systemic circulation together with a number of inactive conjugates at later time points.</p><p>&nbsp;</p><p>Elimination</p><p>Platinum is predominantly excreted in urine, with clearance mainly in the 48 hours following administration.</p><p>By day 5, approximately 54 % of the total dose was recovered in the urine and &lt; 3 % in the faeces.</p><p>&nbsp;</p><p>A significant decrease in clearance from 17.6 &plusmn; 2.18 l/h to 9.95 &plusmn; 1.91 l/h in renal impairment was observed together with a statistically significant decrease in distribution volume from 330 &plusmn; 40.9 to 241 &plusmn; 36.1 l.</p><p>&nbsp;</p><p>Special populations</p><p>&nbsp;</p><p>Renal impairment</p><p>&nbsp;</p><p>The effect of renal impairment on the disposition of oxaliplatin was studied in patients with varying degrees of renal function. Oxaliplatin was administered at a dose of 85 mg/m2 in the</p><p>control group with a normal renal function (CLcr &gt;80 ml/min, n=12) and in patients with mild (CLcr = 50 to 80 ml/min, n=13) and moderate (CLcr = 30 to 49 ml/min, n=11) renal impairment,</p><p>and at a dose of 65 mg/m2 in patients with severe renal impairment (CLcr &lt;30 ml/min, n=5).</p><p>Median exposure was 9, 4, 6, and 3 cycles, respectively, and PK data at cycle 1 were obtained in 11, 13, 10, and 4 patients respectively. There was an increase in plasma ultrafiltrate (PUF) platinum AUC, AUC/dose and a decrease in total and renal CL and Vss with increasing renal impairment especially in the (small) group of patients with severe renal impairment: point estimate (90% CI) of estimated mean ratios by renal status versus normal renal function for AUC/dose were 1.36 (1.08, 1.71), 2.34 (1.82, 3.01) and 4.81 (3.49, 6.64) for patients with mild and moderate and in severe renal failure respectively.</p><p>&nbsp;</p><p>Elimination of oxaliplatin is significantly correlated with the creatinine clearance. Total PUF platinum CL was respectively 0.74 (0.59, 0.92), 0.43 (0.33, 0.55) and 0.21 (0.15, 0.29) and for Vss respectively</p><p>0.52 (0.41, 0.65), 0.73 (0.59, 0.91) and 0.27 (0.20, 0.36) for patients with mild, moderate and severe renal failure respectively. Total body clearance of PUF platinum was therefore reduced by respectively 26% in mild, 57% in moderate, and 79% in severe renal impairment compared to patients with normal function. Renal clearance of PUF platinum was reduced in patients with impaired renal function by 30% in mild, 65% in moderate, and 84% in severe renal impairment compared to patients with normal function.</p><p>There was an increase in beta half life of PUF platinum with increasing degree of renal impairment mainly in the severe group. Despite the small number of patients with severe renal dysfunction, these data are of concern in patients in severe renal failure and should be taken into account when prescribing oxaliplatin in patients with renal impairment (see sections 4.2, 4.3, and 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The target organs identified in preclinical species (mice, rats, dogs, and/or monkeys) in single- and multiple-dose studies included the bone marrow, the gastrointestinal system, the kidney, the testes, the nervous system, and the heart. The target organ toxicities observed in animals are consistent with those produced by other platinum-containing medicinal products and DNA-damaging, cytotoxic</p><p>medicinal products used in the treatment of human cancers with the exception of the effects produced on the heart. Effects on the heart were observed only in the dog and included electrophysiological disturbances with lethal ventricular fibrillation. Cardiotoxicity is considered specific to the dog not only because it was observed in the dog alone but also because doses similar to those producing lethal cardiotoxicity in dogs (150 mg/m2) were well-tolerated by humans. Preclinical studies using rat sensory neurons suggest that the acute neurosensory symptoms related to Oxaliplatin may involve an interaction with voltage-gated Na+ channels.</p><p>&nbsp;</p><p>Oxaliplatin was mutagenic and clastogenic in mammalian test systems and produced embryo-fetal toxicity in rats. Oxaliplatin is considered a probable carcinogen, although carcinogenic studies have not been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The diluted medicinal product should not be mixed with other medications in the same infusion bag or infusion line. Under instructions for use described in section 6.6, oxaliplatin can be co- administered with folinic acid (FA) via a Y-line.</p><p>&nbsp;</p><p>&middot; DO NOT mix with alkaline medicinal products or solutions, in particular 5-fluorouracil, trometamol and folinic acid products containing trometamol as an excipient and trometamol salts of other medicinal products. Alkaline medicinal products or solutions will adversely affect the stability of oxaliplatin (see section 6.6).</p><p>&middot; DO NOT dilute oxaliplatin with saline or other solutions containing chloride ions (including calcium, potassium or sodium chlorides)</p><p>&middot; DO NOT mix with other medicinal products in the same infusion bag or infusion line (see section</p><p>6.6 for instructions concerning simultaneous administration with folinic acid).</p><p>&middot; DO NOT use injection equipment containingaluminium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medicinal product as packaged for sale: 24 months



In-use stability after dilution

From a microbiological point of view, the product should be used immediately.

If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

Chemical and physical in-use stability has been demonstrated for 48 hours at 2 to 8 °C when diluted to the concentrations of 0.2 mg/ml and 2.0 mg/ml with glucose 5% as well as for 6 hours at 20-25 °C when diluted to the concentration of 0.2 mg/ml and 2.0 mg/ml with glucose 5%
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep the vial in the outer carton in order to protect from light. Do not freeze.</p><p>Do not store above 30&deg;C.</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colourless glass vials with grey Halobutyl rubber stoppers and aluminium seals with plastic flip-off caps, with or without a protective plastic overwrap (OncoSafe&reg; ).</p><p>&nbsp;</p><p>Pack sizes:</p><p>50mg/10ml: 1 vial, 5 vials, 10 vials</p><p>100mg/20ml: 1 vial</p><p>150mg/30ml: 1 vial</p><p>200mg/40ml: 1 vial</p><p>250mg/50ml: 1 vial</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other potentially toxic compounds, caution should be exercised when handling and preparing oxaliplatin solutions.</p><p>&nbsp;</p><p><u>Instructions for Handling</u></p><p>&nbsp;</p><p>The handling of this cytotoxic agent by healthcare personnel requires every precaution to guarantee the protection of the handler and his surroundings.</p><p>&nbsp;</p><p>The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicines used, in conditions that guarantee the integrity of the product, the protection of the environment and in particular the protection of the personnel handling the medicines, in accordance with the hospital policy. It requires a preparation area reserved for this purpose. It is forbidden to smoke, eat or drink in this area.</p><p>&nbsp;</p><p>Personnel must be provided with appropriate handling materials, notably long sleeved gowns, protection masks, caps, protective goggles, sterile single-use gloves, protective covers for the work area, containers and collection bags for waste.</p><p>&nbsp;</p><p>Excreta and vomit must be handled with care.</p><p>Pregnant women must be warned to avoid handling cytotoxic agents.</p><p>&nbsp;</p><p>Any broken container must be treated with the same precautions and considered as contaminated waste. Contaminated waste should be incinerated in suitably labelled rigid containers. See below section &ldquo;Disposal&rdquo;.</p><p>&nbsp;</p><p>If oxaliplatin concentrate or solution for infusion should come into contact with skin, wash immediately and thoroughly with water.</p><p>If oxaliplatin concentrate or solution for infusion should come into contact with mucous membranes, wash immediately and thoroughly with water.</p><p>&nbsp;</p><p><u>Special precautions for administration</u></p><p>&nbsp;</p><p>&middot; DO NOT use injection material containingaluminium.</p><p>&middot; DO NOT administer undiluted.</p><p>&middot; Only glucose 5% infusion solution is to be used as a diluent. DO NOT dilute for infusion with sodium chloride or chloride containingsolutions.</p><p>&middot; DO NOT mix with any other medicinal products in the same infusion bag or administer simultaneously by the same infusion line.</p><p>&middot; DO NOT mix with alkaline medicinal products or solutions, in particular 5-fluorouracil, folinic acid products containing trometamol as an excipient and trometamol salts of other products. Alkaline medicinal products or solution will adversely affect the stability of oxaliplatin.</p><p>&nbsp;</p><p><u>Instructions for use with folinic acid (as calcium folinate or disodium folinate)</u></p><p>Oxaliplatin 85mg/m&sup2; IV infusion in 250 to 500 ml of 5% glucose solution is given at the same time as folinic acid IV infusion in 5% glucose solution, over 2 to 6 hours, using a Y-line placed immediately before the site of infusion. These two medicinal products should not be combined in the same infusion bag. Folinic acid must not contain trometamol as an excipient and must only be diluted using isotonic 5% glucose solution, never in alkaline solutions or sodium chloride or chloride containing solutions.</p><p>&nbsp;</p><p><u>Instruction for use with 5-fluorouracil</u></p><p><strong>Oxaliplatin should always be administered before fluoropyrimidines &ndash; i.e. 5-fluorouracil.</strong></p><p>After oxaliplatin administration, flush the line and then administer 5-fluorouracil.</p><p>For additional information on medicinal products combined with oxaliplatin, see the corresponding manufacturer&#39;s summary of product characteristics.</p><p>&nbsp;</p><p><u>Concentrate for solution for infusion</u></p><p>Inspect visually prior to use. Only clear solutions free from visible particles should be used. This medicinal product is for single use only. Any unused concentrate should be discarded.</p><p>&nbsp;</p><p><u>Dilution for intravenous infusion</u></p><p>Withdraw the required amount of concentrate from the vial(s) and then dilute with 250 ml to 500 ml of a 5 % glucose solution to give an oxaliplatin concentration not less than 0.2 mg/ml.</p><p>&nbsp;</p><p>Administer by intravenous infusion.</p><p>&nbsp;</p><p>&nbsp;</p><p>From a microbiological point of view, the product should be used immediately.</p><p>&nbsp;</p><p>If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 - 8&deg;C, unless dilution has taken place in controlled and validated aseptic conditions.</p><p>&nbsp;</p><p>Chemical and physical in-use stability has been demonstrated for 48 hours at 2 to 8 &deg;C when diluted to the concentrations of 0.2 mg/ml and 2.0 mg/ml with glucose 5% as well as for 6 hours at 20-25 &deg;C when diluted to the concentration of 0.2 mg/ml and 2.0 mg/ml with glucose 5%.</p><p>&nbsp;</p><p>Inspect visually prior to use. Only clear solutions free from visible particles should be used.</p><p>&nbsp;</p><p>The medicinal product is for single use only. Any unused infusion solution should be discarded (see chapter &ldquo;disposal&rdquo; below).</p><p>&nbsp;</p><p>NEVER use sodium chloride solution for dilution.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Infusion</u></p><p>The administration of oxaliplatin does not require prehydration.</p><p>&nbsp;</p><p>Oxaliplatin diluted in 250 to 500 ml of a 5 % glucose solution to give a concentration not less than 0.2 mg/ml must be infused either by peripheral vein or central venous line over 2 to 6 hours. When oxaliplatin is administered with 5-fluorouracil, the oxaliplatin infusion must precede the administration of 5-fluorouracil.</p><p>&nbsp;</p><p><u>Disposal</u></p><p>Remnants of the medicinal product as well as all materials that have been used for dilution and administration must be destroyed according to hospital standard procedures applicable to cytotoxic agents and in accordance with local requirements related to the disposal of hazardous waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hexal AG, Holzkirchen, Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>